Netupitant (formerly CID-6451149; AGE-94200; Ro 67-3189) is an orally bioavailable neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. It inhibits NK1 with a Ki of 0.95 nM. The combination drug netupitant/palonosetron was approved by FDA in 2018 for prevention of acute and delayed chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapy such as with cisplatin. Netupitant competitively binds to and blocks the activity of the human substance P/NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in the prevention of chemotherapy-induced nausea and vomiting (CINV).

纯度：≥98%

CAS：290297-26-6